The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Golcadomide and iberdomide are set to feature at EHA.
A Libtayo combo fails to beat Keytruda in first-line melanoma.
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
